找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Bisphosphonates in Clinical Oncology; The Development of P Beat Thürlimann Book 1999 Springer-Verlag Berlin · Heidelberg 1999 Metastatic Bo

[复制链接]
查看: 28633|回复: 35
发表于 2025-3-21 18:14:58 | 显示全部楼层 |阅读模式
期刊全称Bisphosphonates in Clinical Oncology
期刊简称The Development of P
影响因子2023Beat Thürlimann
视频video
发行地址Important pathophysiological background of bone complications.Treatment possibilities
学科分类Recent Results in Cancer Research
图书封面Titlebook: Bisphosphonates in Clinical Oncology; The Development of P Beat Thürlimann Book 1999 Springer-Verlag Berlin · Heidelberg 1999 Metastatic Bo
影响因子This book provides a clinically oriented overview on the patho-physiological background and the use of bisphosphonates in oncology. The clinical development of pamidronate to treat tumor-induced hypercalcemia and malignant osteolytic bone disease is demonstrated, as well as the results of pivotal studies. New important findings on how to best use pamidronate in certain indications are given and put in perspective. The author discusses patient management guidelines as well as pharmaco-economic aspects important for the readers.
Pindex Book 1999
The information of publication is updating

书目名称Bisphosphonates in Clinical Oncology影响因子(影响力)




书目名称Bisphosphonates in Clinical Oncology影响因子(影响力)学科排名




书目名称Bisphosphonates in Clinical Oncology网络公开度




书目名称Bisphosphonates in Clinical Oncology网络公开度学科排名




书目名称Bisphosphonates in Clinical Oncology被引频次




书目名称Bisphosphonates in Clinical Oncology被引频次学科排名




书目名称Bisphosphonates in Clinical Oncology年度引用




书目名称Bisphosphonates in Clinical Oncology年度引用学科排名




书目名称Bisphosphonates in Clinical Oncology读者反馈




书目名称Bisphosphonates in Clinical Oncology读者反馈学科排名




单选投票, 共有 1 人参与投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:20:24 | 显示全部楼层
Pamidronate,onate might be affected by the rate of administration, a prospective pharmacokinetic study of pamidronate at three different infusion rates was started in the Department of Internal Medicine C, Kantonsspital St. Gallen KSSG, Switzerland and in the Centre Pluridisciplinaire d’Oncologie and the Depart
发表于 2025-3-22 00:47:35 | 显示全部楼层
发表于 2025-3-22 05:12:35 | 显示全部楼层
发表于 2025-3-22 11:43:19 | 显示全部楼层
发表于 2025-3-22 15:46:37 | 显示全部楼层
Torsionsschwingungen in Antriebssystemen,nt. Finally, a prospective, randomized, double-blind, placebo-controlled, three-arm, phase-III study of ibandronate has been conducted in patients with breast cancer and bone metastases (SG 143/94). No results are available to the public so far.
发表于 2025-3-22 17:49:06 | 显示全部楼层
发表于 2025-3-22 21:17:30 | 显示全部楼层
Pamidronate,ew medication and no chemotherapy was started for at least 72 hr prior to entry or at any time during the study. Median creatinine clearance was 66 ml/min (range 37–110 ml/min). Mean age was 63 years (range 28–78 years). Thirty-two of the 37 patients suffered from bone metastases of breast cancer. T
发表于 2025-3-23 05:08:37 | 显示全部楼层
发表于 2025-3-23 09:20:20 | 显示全部楼层
Beat ThürlimannImportant pathophysiological background of bone complications.Treatment possibilities
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-10 03:48
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表